The BPC-157 / TB-500 blend combines two of the most-studied repair-research peptides into a single vial. Because they act through different proposed mechanisms, researchers sometimes study them together. Both are research-use-only compounds — not approved for human use.
- BPC-157: a 15-amino-acid peptide from a gastric-juice protein.
- TB-500: a synthetic peptide related to the actin-binding protein Thymosin β4.
- Why blend: complementary, non-overlapping proposed mechanisms.
- Status: neither is FDA-approved; research use only.
What is the BPC-157 / TB-500 blend?
Rather than two separate vials, the blend supplies both peptides together. It pairs BPC-157, studied for angiogenesis and gastrointestinal models, with TB-500, studied for actin regulation and cell migration.
| BPC-157 | TB-500 | |
|---|---|---|
| Type | Pentadecapeptide (15 aa) | Thymosin β4 fragment |
| Proposed focus | Angiogenesis, GI repair | Cell migration, actin regulation |
| Lab form | Lyophilized | Lyophilized |
Why they’re studied together
The two peptides approach repair research from different angles — one emphasizes blood-vessel formation and gut models, the other cytoskeletal dynamics and cell movement. Because the proposed pathways are complementary rather than redundant, the combination is of interest in models where both processes are relevant. For a full breakdown of the differences, see BPC-157 vs TB-500.
Storage & handling
The blend is supplied lyophilized. Keep it cold and away from light, reconstitute only when needed for research, and limit freeze–thaw cycles. See our guide on reconstituting lyophilized peptides.
Research status
Neither BPC-157 nor TB-500 is approved by the FDA for human use, and both are prohibited in competitive sport. The available evidence is preclinical. Treat the blend strictly as a research compound.
Looking for the research-grade BPC-157 / TB-500 blend?
Lab-tested, with third-party purity verification.